

Appendix 1. Treatment Impact on Blood Creatine Phosphokinase in the Five Patients Who Experienced Elevated Levels as an Adverse Event (Safety Population)

Patient	Medical History	Treatment	Creatine Phosphokinase (U/L)*				Other Adverse Events Reported
			Screening	Baseline	End of Treatment	End of Follow-up	
36-year-old black female	Obesity	Ulipristal 5 mg	175	265	255	388	None
43-year-old white female	None	Ulipristal 5 mg	69	253	66	95	Cellulitis, dermatitis contact, allergy to arthropod bite
41-year-old black female	None	Ulipristal 10 mg	60	316	-	40	None
45-year-old black female	Hypertension	Ulipristal 10 mg	255	222	376	238	Platelet count increased, blood cholesterol increased, pain in extremity
41-year-old black female	None	Ulipristal 10 mg	86	138	299	117	None

*CPK normal range = 33-211 U/L.

CPK, creatine phosphokinase

Simon JA, Catherino W, Segars JH, Blakesley RE, Chan A, Sniukiene V, et al. Ulipristal acetate for treatment of symptomatic uterine fibroids/leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2018; 131.

The authors provided this information as a supplement to their article.

©2018 American College of Obstetricians and Gynecologists.